News
Public · Published
Most and least shorted mid- to mega-cap healthcare stocks at the end of October
Short interest data from late October 2026 shows bearish bets concentrated in biotechnology, equipment, and digital health stocks. Recursion Pharmaceuticals leads at 27.13% short interest, followed by Tango Therapeutics at 26.56%, while Johnson & Johnson and Eli Lilly remain below 0.90% at 0.70% and 0.78%.
Published:
Updated:
What happened
Short interest data from late October 2026 shows bearish bets concentrated in biotechnology, equipment, and digital health stocks. Recursion Pharmaceuticals leads at 27.13% short interest, followed by Tango Therapeutics at 26.56%, while Johnson & Johnson and Eli Lilly remain below 0.90% at 0.70% and 0.78%.
Confirmed
Global impact / market context
High short interest means many investors have borrowed and sold shares hoping to buy them back cheaper, signaling doubt about these companies' prospects. This concentration in speculative biotech versus defensive pharma giants shows investors are placing risky bets on volatile names while seeking safety in stable, established drugmakers.
Analyst inference
Healthcare stocks have outperformed broadly, with the Health Care Select Sector SPDR Fund up 19.43% year-to-date versus the S&P 500's 10.73% gain, and healthcare carries a 12.1% index weighting. Yet short sellers still target speculative biotech, gene-editing, and precision oncology developers, while traditional pharma anchors enjoy strong institutional support with minimal short exposure.
Analyst inference
What to watch
- Recursion Pharmaceuticals, Tango Therapeutics, and Beam Therapeutics all carry short interest above 26.26%, meaning any positive trial results or partnership news could trigger sharp buying pressure and rapid share price swings. Confirmed
- Watch whether short sellers reduce positions in speculative biotech names if clinical trial data improves, which would signal changing risk appetite and potentially lift the most heavily shorted stocks. Analyst inference
- Monitor whether defensive pharma giants like Johnson & Johnson and Eli Lilly maintain minimal short interest, as rising bearish bets there would indicate investors growing cautious about traditionally stable healthcare anchors. Analyst inference